Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.59 |
| ▸ | LIPE | Q05469 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.47 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.47 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TSPO | P30536 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29889491 | 1.00 | ENPP2 (0.59) | ENPP2LIPECA1CA2LMNA | |
| SCHEMBL28646988 | 0.86 | ENPP2 (0.53) | ENPP2LIPECA1CA2LMNA | |
| SCHEMBL3790554 | 0.84 | ENPP2 (0.47) | ENPP2LIPECA1CA2LMNA | |
| SCHEMBL3786173 | 0.83 | ENPP2 (0.46) | ENPP2LIPECA1CA2LMNA | |
| SCHEMBL9946021 | 0.83 | LMNA (0.48) | LMNAGAAKMT2ALTA4HTSHR | |
| SCHEMBL6359459 | 0.82 | LMNA (0.52) | CA1CA2LMNAGAAKMT2A | |
| SCHEMBL4556707 | 0.81 | SLC6A4 (0.51) | ENPP2LIPEGAAKMT2AORAI1 | |
| SCHEMBL28632181 | 0.81 | ALDH1A1 (0.60) | ENPP2LIPELMNAGAAKMT2A | |
| SCHEMBL28636681 | 0.81 | ENPP2 (0.58) | ENPP2LMNAKMT2AORAI1ORAI2 | |
| SCHEMBL3789064 | 0.80 | CA1 (0.55) | ENPP2LIPECA1CA2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 515 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425510-A1 | PROCESS FOR THE PREPARATION OF ZANUBRUTINIB | OLON S.P.A. (IT) | 2024-12-26 | — | — | US | claimed |
| CN-118878402-A | Preparation method of trifluoromethyl ketone compound based on palladium catalysis of C-N bond cleavage | 大连理工大学 | 2024-11-01 | — | — | CN | claimed |
| EP-4416149-A1 | PROCESS FOR THE PREPARATION OF ZANUBRUTINIB | OLON S.p.A. (IT) | 2024-08-21 | — | — | EP | claimed |
| CN-117865773-A | Preparation method of difluoromethyl aromatic compound based on palladium-catalyzed decarbonylation coupling | 大连理工大学 | 2024-04-12 | — | — | CN | claimed |
| WO-2023062504-A1 | PROCESS FOR THE PREPARATION OF ZANUBRUTINIB | OLON S.P.A. (IT) | 2023-04-20 | — | — | WO | claimed |
| CN-111072696-A | Synthesis method of 2-phenoxyphenylboronic acid | 苏州汉德创宏生化科技有限公司 | 2020-04-28 | — | — | CN | claimed |
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | claimed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| CN-115210894-B | Thienothiophene derivatives of disubstituted radicals diaryloxybenzos heterodiazole compounds | 艾尼股份公司 | 2026-02-27 | — | — | CN | disclosed |
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| EP-4218934-B1 | INHIBITING UBIQUITIN-SPECIFIC PROTEASE 30 (USP30) | FORMA THERAPEUTICS INC (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-117756781-B | Indole histone deacetylase family inhibitor with anti-tumor effect | 沈阳药科大学 | 2025-06-13 | — | — | CN | disclosed |
| EP-1351686-A2 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDINES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2003-10-15 | — | — | EP | disclosed |
| US-6624180-B2 | Such as 2-(2-(N-((4-aminoiminomethylphenyl)methyl)-3-(3-aminophenyl)-6-(N,N -dimethylhydrazino)-1-oxypyridinyl))acetami de which inhibit serine proteases for preventing and treating thrombotis | PHARMACIA CORPORATION | 2003-09-23 | — | — | US | disclosed |
| US-20030139401-A9 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDINES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION | 2003-07-24 | — | — | US | disclosed |
| US-20020198199-A1 | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2002-12-26 | — | — | US | disclosed |
| WO-2002042272-A2 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDINES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | ENPP2 2205/4885LIPE 3467/4885CA1 4800/4885 |
| US-20240425510-A1 | PROCESS FOR THE PREPARATION OF ZANUBRUTINIB | BCL6B, BCL6, BCL9 | ENPP2 2615/4885LIPE 2221/4885CA1 4874/4885 |
| US-20020198199-A1 | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade | TFPI, F2, PLAT | ENPP2 189/4885LIPE 1442/4885CA1 2593/4885 |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | GFER, MUC1, CTH | ENPP2 854/4885LIPE 1452/4885CA1 1918/4885 |
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | ENPP2 504/4885LIPE 983/4885CA1 702/4885 |
| US-20030139401-A9 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDINES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | TFPI, F2, PLAT | ENPP2 189/4885LIPE 1442/4885CA1 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.